EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score

Benoît Guillet, Maxime Pawlowski, Pierre Boisseau, Yohann Répessé, Philippe Beurrier, Sophie Bayart, Xavier Delavenne iD, Marc Trossaërt, Peter J Lenting

Thrombosis and Haemostasis · 2024-10 · 124 (10) · 922-936

DOI: 10.1055/a-2329-3375 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 11.06.2024. Verfasst von Benoît Guillet und 8 weiteren Autor:innen. Beteiligte Einrichtung: CRH, CRC-MHC (Centre de Référence de l'Hémophilie, Centre de Ressource et de Compétence des Maladies Hémorragiques Constitutionnelles), University Ho…. Hauptthemen laut MEDLINE: Deamino Arginine Vasopressin, Factor VIII, Hemophilia A. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: GIRCI-HUGO, CoMETH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Desmopressin (DDAVP) is used in patients with moderate/mild hemophilia A (PWMHs) to increase their factor VIII (FVIII) level and, if possible, normalize it. However, its effectiveness varies between individuals. The GIDEMHA study aims to investigate the influence of F8 gene variants. Material and Methods The study collected the trajectory of FVIII levels from therapeutic intravenous DDAVP tests in four French hemophilia treatment centers. A pharmacological analysis was performed associated with efficacy scores according to F8 variants: absolute and relative responses, as well as new scores: absolute duration (based on duration with FVIII ≥ 0.50 IU.mL−1) and relative duration (based on half-life).

Results

From enrolled 439 PWMHs, 327 had a hot-spot F8 variant (with ≥5 PWMHs). For these, the median (min–max) basal and peak FVIII were 0.20 (0.02–0.040) and 0.74 (0.14–2.18) IU.mL−1 respectively, with FVIII recovery being 3.80 IU.ml−1 (1.15–14.75). The median FVIII half-life was 3.9 hours (0.7–15.9 hours). FVIII was normalized (≥0.50 IU.mL−1) in 224/327 PWMHs (69%) and the median time with normalized FVIII was 3.9 hours (0.0–54.1 hours). Following the response profiles to DDAVP defined by the four efficacy scores, four groups of F8 variants were isolated, and then compared using survival curves with normalized FVIII (p < 0.0001): “long-lastingly effective” [p.(Glu739Lys), p.(Ser2030Asn), p.(Arg2178His), p.(Gln2208Glu), and T-stretch deletion in intron 13]; “moderately effective” [p.(Ser112Phe), p.(Ala219Thr), p.(Thr2105Ile), p.Phe2146Ser), and p.(Asp2150Asn)]; “moderately ineffective” [p.Ala81Asp), p.(Gln324Pro), p.(Tyr492His), p.(Arg612Cys), p.(Met701Val), p.(Val2035Asn), and p.(Arg2178Cys)]; and “frequently ineffective” [c.-219C > T, p.(Cys2040Tyr), p.(Tyr2169His), p.(Pro2319Leu), and p.(Arg2326Gln)].

Conclusion

In view of our data, we propose indications for DDAVP use in PWMH based on F8 variants for minor and major invasive procedures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deamino Arginine VasopressinFactor VIIIHemophilia AAdolescentAdultChildHumansMaleMiddle AgedYoung AdultFranceGenotypeHalf-LifeHemostaticsTreatment Outcome

Substanzen

Deamino Arginine VasopressinF8 protein, humanFactor VIIIHemostatics

Autor:innen und Institutionen

  • CRH, CRC-MHC (Centre de Référence de l'Hémophilie, Centre de Ressource et de Compétence des Maladies Hémorragiques Constitutionnelles), University Hospital, Rennes, France.
  • Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, Environnement et Travail). UMR_S 1085, Rennes, France.
  • Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, CHU de Nantes, France.
  • Haemophilia Treatment Center, University Hospital of Caen, Caen, France.
  • Haemophilia Treatment Center, University Hospital of Angers, Pays de la Loire, France.
  • INSERM, UMR 1059, Dysfonction Vasculaire et de l'Hémostase, Université de Lyon, Saint Etienne, France.

ORCID-Profile: Xavier Delavenne

Förderung

  • GIRCI-HUGO
  • CoMETH

Zitieren

APA

Guillet, B., Pawlowski, M., Boisseau, P., Répessé, Y., Beurrier, P., Bayart, S., Delavenne, X., Trossaërt, M., & Lenting, P. J. (2024). Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score. Thrombosis and Haemostasis, 124(10), 922-936. https://doi.org/10.1055/a-2329-3375

Vancouver

Guillet B, Pawlowski M, Boisseau P, Répessé Y, Beurrier P, Bayart S, et al. Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score. Thrombosis and Haemostasis. 2024;124(10):922-936. doi:10.1055/a-2329-3375

BibTeX
@article{Guillet2024,
  author = {Guillet, Benoît and Pawlowski, Maxime and Boisseau, Pierre and Répessé, Yohann and Beurrier, Philippe and Bayart, Sophie and Delavenne, Xavier and Trossaërt, Marc and Lenting, Peter J},
  title = {Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {10},
  pages = {922--936},
  doi = {10.1055/a-2329-3375}
}
Kostenlos starten →